Biodel Inc. (NASDAQ:ALBO)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research note issued to investors on Monday, September 11th. They currently have a $58.00 target price on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 158.01% from the stock’s current price. Wedbush also issued estimates for Biodel’s Q3 2017 earnings at ($0.76) EPS, Q4 2017 earnings at ($0.77) EPS, FY2017 earnings at ($3.38) EPS, Q1 2018 earnings at ($0.76) EPS, Q2 2018 earnings at ($0.76) EPS, Q3 2018 earnings at ($0.77) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($3.06) EPS, FY2019 earnings at ($3.06) EPS, FY2020 earnings at ($3.25) EPS and FY2021 earnings at ($0.68) EPS.
A number of other equities research analysts also recently commented on ALBO. Zacks Investment Research downgraded Biodel from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Cowen and Company began coverage on Biodel in a research report on Wednesday, August 16th. They set an “outperform” rating for the company. Finally, Needham & Company LLC began coverage on Biodel in a research report on Tuesday, July 18th. They set a “buy” rating and a $35.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.33.
Biodel (NASDAQ ALBO) traded down 1.40% during trading on Monday, hitting $21.85. The stock had a trading volume of 1,923 shares. The stock’s market cap is $194.07 million. The firm’s 50-day moving average price is $23.53 and its 200-day moving average price is $22.43. Biodel has a 1-year low of $12.00 and a 1-year high of $37.69.
Biodel (NASDAQ:ALBO) last announced its quarterly earnings data on Monday, August 21st. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). On average, equities research analysts predict that Biodel will post ($3.64) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Biodel’s (ALBO) Outperform Rating Reaffirmed at Wedbush” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/biodels-albo-outperform-rating-reiterated-at-wedbush/1635206.html.
A hedge fund recently raised its stake in Biodel stock. Renaissance Technologies LLC grew its holdings in Biodel Inc. (NASDAQ:ALBO) by 0.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,632 shares of the biopharmaceutical company’s stock after purchasing an additional 794 shares during the period. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 as of its most recent SEC filing. Institutional investors own 27.36% of the company’s stock.
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with our FREE daily email newsletter.